[Effects and toxicity of neoadjuvant chemotherapy with vinorelbine and cisplatin in treatment of operable breast cancer previously non-responsive to anthracyclines and taxanes-containing regimen: analysis of 19 cases].
To evaluate the short-term effects and toxicity of vinorelbine combined with cisplatin (NP) as a neoadjuvant chemotherapy regimen in treatment of operable breast cancer non-responsive to the combination of anthracyclines and taxanes. Nineteen breast cancer patients, all female, who failed to achieve complete remission (CR) or partial remission (PR) to the combination of anthracyclines and taxanes as neoadjuvant regimen were treated with 2 cycles of NP regimen (vinorelbine 25 mg/m(2), on days 1 and 8 and cisplatin 70 mg/m(2), on days 1 and 3, both by intravenous infusion, as a cycle). The clinical objective response was evaluated with dynamic contrast-enhanced MRI of the breast before operation and the pathological response was evaluated by pathological examination. The toxicity of the NP regimen was evaluated according to National Cancer Institute-Common Toxicity Criteria v.3.0. The CR + PR rate of the NP regime was 52.6% (10/19), and pathological response (G(2) + G(3) + G(4) + G(5)) was found in 17 cases (89.5%, 17/19). The most common toxicities were neutropenia and nausea/vomiting. These toxicities were reversible and did not cause death. A well-tolerated and effective regimen for breast cancer patient who fail to respond to the combination of anthracyclines and taxanes neoadjuvant chemotherapy, the NP regimen can be considered as an effective choice of second-line regimen. It can be considered as an effective choice of second-line regimen.